Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of Eltrombopag and rhTPO for ITP
NCT04518878Phase 1Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2020
- Primary completion
- Dec 2021
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eltrombopag and recombinant human thrombopoietin in immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Primary endpoints: Complete response at 6 weeks, Response at 6 weeks and 2 more. Status: unknown.
02
Drugs
eltrombopagrecombinant human thrombopoietin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04518878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518878.